Published in Eur J Pharmacol on December 03, 1981
Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs. Br J Clin Pharmacol (1991) 0.93
An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol (1984) 0.91
Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure. Drugs (1990) 0.85
A new class of angiotensin-converting enzyme inhibitors. Nature (1980) 3.03
Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci U S A (1991) 2.67
Enhancement of the humoral response of T cell-depleted murine spleens by a factor derived from human monocytes in vitro. J Immunol (1974) 1.49
Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. J Pharmacol Exp Ther (1981) 1.44
Specific membrane receptors for atrial natriuretic factor in renal and vascular tissues. Proc Natl Acad Sci U S A (1984) 1.41
Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens (1995) 1.40
The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant (2008) 1.33
Anger regulation deficits in combat-related posttraumatic stress disorder. J Trauma Stress (1997) 1.30
Renin release after hemorrhage and after suprarenal aortic constriction in dogs without sodium delivery to the macula densa. Circ Res (1970) 1.29
Endocarditis in high-risk neonates. Pediatrics (1983) 1.29
High-frequency scrotal sonography. AJR Am J Roentgenol (1983) 1.29
Potentiation of adrenergic venomotor responses by angiotensin, prostaglandin F 2 and cocaine. J Pharmacol Exp Ther (1971) 1.26
Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther (1981) 1.22
Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry (1994) 1.22
Unique use of a tip-deflecting guide wire in removing a catheter embolus from an infant. Pediatr Cardiol (1987) 1.20
Attenuation of hydrochlorothiazide-induced hypokalemia in dogs by a beta-adrenergic blocking drug, timolol. Eur J Pharmacol (1975) 1.20
Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest (1993) 1.12
Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. J Med Chem (1999) 1.09
Evidence for a renal vascular receptor in control of renin secretion. Am J Physiol (1971) 1.07
Ventricular atrial natriuretic factor in the cardiomyopathic hamster model of congestive heart failure. Circ Res (1988) 1.03
The biochemical pharmacology of atrial peptides. Annu Rev Pharmacol Toxicol (1989) 1.00
Acute and chronic angiotensin hypertension: neural and nonneural components, time course, and dose dependency. Am J Physiol (1996) 0.99
2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution. J Med Chem (1980) 0.97
Water drinking induced in sheep by angiotensin--a physiological or pharmacological effect? J Comp Physiol Psychol (1975) 0.96
Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension (1995) 0.95
Differential effects of prostaglandins E 1 , E 2 , F 1 and F 2 on adrenergic vasoconstriction in the dog hindpaw. J Pharmacol Exp Ther (1971) 0.95
Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med (1996) 0.94
Plasma and atrial content of atrial natriuretic factor in cardiomyopathic hamsters. Life Sci (1986) 0.93
Novel renin inhibitors containing the amino acid statine. Nature (1983) 0.93
In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J Pharmacol Exp Ther (1992) 0.92
Isolation and sequence determination of peptide components of atrial natriuretic factor. Biochem Biophys Res Commun (1984) 0.91
R-enantiomer of timolol: a potential selective ocular antihypertensive agent. Graefes Arch Clin Exp Ophthalmol (1984) 0.90
The large-scale isolation of renin-containing granules from rabbit renal cortex by zonal centrifugation. J Lab Clin Med (1975) 0.90
Interaction of non-guanylate cyclase-linked atriopeptin receptor ligand and endopeptidase inhibitor in conscious rats. J Pharmacol Exp Ther (1989) 0.88
Renal and systemic effects of synthetic atrial natriuretic factor. Life Sci (1985) 0.88
Water intake in hypovolemic sheep: effects of crushing the left atrial appendage. Science (1981) 0.88
Enhancement of the antihypertensive effect of hydrochlorothiazide in dogs after suppression of renin release by beta-adrenergic blockade. Clin Sci Mol Med (1975) 0.87
Thiorphan, an inhibitor of endopeptidase 24.11, potentiates the natriuretic activity of atrial natriuretic peptide. J Cardiovasc Pharmacol (1989) 0.87
A central osmosensitive receptor for renal sodium excretion. J Physiol (1975) 0.87
Area postrema and sympathetic nervous system effects of vasopressin and angiotensin II. Clin Exp Pharmacol Physiol (2000) 0.87
A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension (1995) 0.86
Cognitive-behavioral treatment for severe anger in posttraumatic stress disorder. J Consult Clin Psychol (1997) 0.86
Transfer of training from differential classical to differential instrumental conditioning. J Exp Psychol (1968) 0.86
Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press (1996) 0.86
Atrial rupture in a child from cardiac massage by his parent. Ann Thorac Surg (1987) 0.86
Influence of angiotensin I, angiontensin II and cocaine on adrenergic vasoconstrictor responses in the dog hindpaw. J Pharmacol Exp Ther (1972) 0.86
Central inhibition of reflex vasodilatation by angiotensin and reduced renal pressure. Am J Physiol (1970) 0.86
Enhancement of sympathetic neurotransmission by prostaglandin F 2 in the cutaneous vascular bed of the dog. Eur J Pharmacol (1972) 0.86
Renal function and renin secretion after administration of ouabain and ouabain plus furosemide in conscious sheep. Circ Res (1978) 0.85
The role of ACTH and adrenal glucocorticoids in the salt appetite of wild rabbits (Oryctolagus cuniculus (L)). Endocrinology (1975) 0.85
Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens (1995) 0.84
Pediatric aspects of essential hypertension. J Am Diet Assoc (1982) 0.84
Inhibition of mammalian soluble guanylate cyclase activity by adenosine 5'-tetraphosphate, guanosine 5'-tetraphosphate and other nucleotides. J Cyclic Nucleotide Res (1977) 0.84
Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. J Med Chem (1985) 0.84
Central and peripheral actions of a nonpeptidic angiotensin II receptor antagonist. Hypertension (1990) 0.83
Pharmacological properties of the converting enzyme inhibitor, enalapril maleate (MK-421). Fed Proc (1983) 0.83
Mechanisms regulating the renal excretion of sodium during pregnancy. J Clin Invest (1970) 0.83
Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets. J Pharmacol Exp Ther (1998) 0.83
Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. J Hypertens Suppl (1995) 0.83
Mechanism of natriuresis during intrarenal infusion of prostaglandins. Am J Physiol (1984) 0.83
Cardiac and hemodynamic responses to synthetic atrial natriuretic factor in rats. Life Sci (1987) 0.83
Enhanced erythropoietin and prostaglandin E production in the dog following renal artery constriction. Proc Soc Exp Biol Med (1976) 0.82
Differences in semantic event-related potentials in learning-disabled, normal, and gifted children. Biofeedback Self Regul (1992) 0.82
Three candidate genes and angiotensin-converting enzyme inhibitor-related cough: a pharmacogenetic analysis. Hypertension (1998) 0.82
In vitro pharmacology of a nonpeptidic angiotensin II receptor antagonist, SC-51316. J Pharmacol Exp Ther (1992) 0.81
Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor. J Pharmacol Exp Ther (1991) 0.81
A new, long-lasting competitive inhibitor of angiotensin. Science (1972) 0.81
Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Press (1997) 0.81
Reversal of low dose angiotension hypertension by angiotensin receptor antagonists. Hypertension (1991) 0.81
Trimethoprim diffusion into prostatic and salivary secretions of the dog. Invest Urol (1973) 0.81
Release of atrial natriuretic factor. Effects of repetitive stretch and temperature. Am J Physiol (1986) 0.81
Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists. J Med Chem (1991) 0.81
Evidence for a renal vascular mechanism in renin release: new observations with graded stimulation by aortic constriction. Circ Res (1971) 0.81
Effects of prostaglandins A2, E2 and F2 alpha on erythropoietin production. J Pharmacol Exp Ther (1976) 0.81
Another humoral substance that enhances adrenergic responsiveness during acute renal ischaemia. Nature (1971) 0.81
Effects of long-term increases in plasma ANP on angiotensin II-induced hypertension. Am J Physiol (1990) 0.81
Blockade of adrenergic vasoconstrictor responses in the dog by prostaglandins E 1 and A 1 . J Pharmacol Exp Ther (1971) 0.80
Comparison of a new renin inhibitor and enalaprilat in renal hypertensive dogs. Hypertension (1987) 0.80
Utilization of swine to study the risk factor of an elevated salt diet on blood pressure. Am J Clin Nutr (1979) 0.80
Zonal centrifugation in reorienting density gradients. Biochim Biophys Acta (1971) 0.80
Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens (1995) 0.80
The character of the atrial natriuretic response: pressure and volume effects. J Hypertens Suppl (1986) 0.80
3-Hydroxy-alpha-methyltyrosine progenitors: synthesis and evaluation of some (2-oxo-1,3-dioxol-4-yl)methyl esters. J Med Chem (1984) 0.80
Increased renin release during renal arteriolar dilatation in dogs. Am J Physiol (1974) 0.79
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. 2. J Med Chem (1986) 0.79
A steady-state control analysis of the renin-angiotensin-aldosterone system. Circ Res (1972) 0.79
Responses to amrinone in isolated cardiac muscles from cat, rabbit, and guinea pig. J Cardiovasc Pharmacol (1984) 0.79
Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man. J Cardiovasc Pharmacol (1993) 0.79
Identification and characterization of endothelin converting activity from EAHY 926 cells: evidence for the physiologically relevant human enzyme. Arch Biochem Biophys (1994) 0.79
Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure. J Hypertens Suppl (1983) 0.79